LRMR Larimar Corp: Year-over-year earnings per share growth for the last twelve months

Official company branding of Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics (LRMR) focuses on developing therapies to combat Friedreich's ataxia, which requires continuous funding. The percentage change in quarterly EPS correlates with these expenditures, while 23.60 determines the latest valuation metric. Streamlined international delivery of biomaterials minimizes disruptions; however, a high dependence on FDA verdicts and the risk of failed trials render the asset volatile.

Larimar Therapeutics, Inc. (LRMR) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/15/2026

Analytical breakdowns for Larimar Therapeutics

- share price and consensus valuation forecast:
Fundamental company analysis:larimartx.com, LRMR
Manufactured product of Larimar Corp

Quarterly EPS growth measures the dynamics of net income per share, reflecting the efficiency of capital generation. Professionals utilize this indicator to assess business scalability and the pace of profitability recovery. By analyzing the quarterly change in earnings per share, an investor determines the asset's stage of financial maturity. For Larimar Therapeutics (LRMR), this metric is critical during the transition to the commercial launch of drugs. A positive trend would confirm the successful deployment of global distribution infrastructure.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|Year-over-year earnings per share growth for the last twelve months DYN (Dyne Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months Edgewise Pharma EWTX|Rapport Corp - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Therapeutics|CTNM: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Capricor Therapeutics CAPR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata